Motif Pharmaceuticals Ltd. 3
3 · Chromocell Therapeutics Corp · Filed Feb 15, 2024
Insider Transaction Report
Form 3
Motif Pharmaceuticals Ltd.
10% Owner
Holdings
- 470,674
Common Stock
Senior Secured Convertible Promissory Note
Exp: 2024-02-29→ Common Stock (12,732 underlying)
Footnotes (2)
- [F1]Represents $61,109.98 of outstanding principal and accrued and unpaid interest of this senior secured convertible promissory note, due February 29, 2024, which will automatically convert into 12,732 shares of common stock of the Issuer at a conversion price of 80.0% of the offering price of the securities sold to the public in the Issuer's initial public offering.
- [F2]Zachary Klein has sole voting and dispositive power over the shares held by the Reporting Person as to which Mr. Klein disclaims beneficial ownership except to the extent of his pecuniary interest therein.